Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Silver

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 16, 2017
The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophreniaReef Einoch, Orly Weinreb, Nina Mandiuk, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 15, 2002
The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic studyMichael Ritsner, Alexander Ponizovsky, Jean Endicott, et al.
Schizophrenia Research|May 6, 2006
Impaired error monitoring contributes to face recognition deficit in schizophrenia patientsHenry Silver, Craig Goodman, Warren Bilker, et al.
International Clinical Psychopharmacology|March 11, 2015
Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patientsHenry Silver, Nina Mandiuk, Reef Einoch, et al.
Medical Informatics and the Internet in Medicine|January 2, 2003
Neural network identification of high-risk suicide patientsIlan Modai, Rena Kurs, Michael Ritsner, et al.
Journal of Psychiatric Research|October 18, 2003
Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patientsMichael Ritsner, Ilan Modai, Anatoly Gibel, et al.
Journal of Clinical Psychopharmacology|September 28, 2002
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effectsChristoph Hiemke, Avi Peled, Mahmoud Jabarin, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 16, 2017
The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophreniaReef Einoch, Orly Weinreb, Nina Mandiuk, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 15, 2002
The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic studyMichael Ritsner, Alexander Ponizovsky, Jean Endicott, et al.
Schizophrenia Research|May 6, 2006
Impaired error monitoring contributes to face recognition deficit in schizophrenia patientsHenry Silver, Craig Goodman, Warren Bilker, et al.
International Clinical Psychopharmacology|March 11, 2015
Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patientsHenry Silver, Nina Mandiuk, Reef Einoch, et al.
Medical Informatics and the Internet in Medicine|January 2, 2003
Neural network identification of high-risk suicide patientsIlan Modai, Rena Kurs, Michael Ritsner, et al.
Journal of Psychiatric Research|October 18, 2003
Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patientsMichael Ritsner, Ilan Modai, Anatoly Gibel, et al.
Journal of Clinical Psychopharmacology|September 28, 2002
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effectsChristoph Hiemke, Avi Peled, Mahmoud Jabarin, et al.
Pageof 5